|
Jun 11
|
IntelGenx Announces Initiation of the Sale and Investment Solicitation Process
|
|
Apr 5
|
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA
|
|
Feb 5
|
Studies Validate Advantages of Administering Drugs to Pets via IntelGenx’s VetaFilm® Platform
|
|
Dec 18
|
IntelGenx Announces New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm®
|
|
Dec 5
|
IntelGenx Announces Closing of Previously Announced Subsequent Non-Brokered Private Placement With atai Life Sciences for Aggregate Gross Proceeds of US$750,000
|
|
Dec 4
|
IntelGenx Announces Changes to its Board of Directors
|
|
Nov 28
|
IntelGenx Announces Shareholder Approval of Financing Transactions
|
|
Nov 6
|
IntelGenx Announces Co-development and Commercialization of Cannabinoid-Infused VersaFilm® Products with Tilray
|
|
Nov 2
|
IntelGenx to Report Third Quarter 2023 Financial Results on November 9, 2023 – Conference Call to Follow
|